OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 66 filers reported holding OCULAR THERAPEUTIX INC in Q1 2018. The put-call ratio across all filers is 0.56 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,901 | -69.0% | 12,389 | -49.1% | 0.00% | – |
| Q2 2023 | $125,486 | -2.1% | 24,319 | 0.0% | 0.00% | – |
| Q1 2023 | $128,161 | +19318.3% | 24,319 | -89.6% | 0.00% | – |
| Q4 2022 | $660 | -99.9% | 234,783 | +60.7% | 0.00% | – |
| Q3 2022 | $607,000 | +39.9% | 146,122 | +35.5% | 0.00% | – |
| Q2 2022 | $434,000 | +422.9% | 107,812 | +544.7% | 0.00% | – |
| Q1 2022 | $83,000 | -29.1% | 16,723 | 0.0% | 0.00% | – |
| Q4 2021 | $117,000 | +234.3% | 16,723 | +46.4% | 0.00% | – |
| Q3 2019 | $35,000 | -30.0% | 11,423 | 0.0% | 0.00% | – |
| Q2 2019 | $50,000 | -47.4% | 11,423 | -52.1% | 0.00% | – |
| Q1 2019 | $95,000 | 0.0% | 23,831 | 0.0% | 0.00% | – |
| Q4 2018 | $95,000 | -52.5% | 23,831 | -18.1% | 0.00% | – |
| Q3 2018 | $200,000 | +13.0% | 29,090 | -26.7% | 0.00% | – |
| Q4 2017 | $177,000 | -27.8% | 39,664 | 0.0% | 0.00% | – |
| Q3 2017 | $245,000 | – | 39,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |